33 related articles for article (PubMed ID: 1506887)
1. In vivo measurement of regional brain and tumor pH using [14C]dimethyloxazolidinedione and quantitative autoradiography. II: Characterization of the extracellular fluid compartment using pH-sensitive microelectrodes and [14C]sucrose.
Arnold JB; Kraig RP; Rottenberg DA
J Cereb Blood Flow Metab; 1986 Aug; 6(4):435-40. PubMed ID: 3733903
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Significance of Arachidonic Acid, a Substrate for Cyclooxygenases, Lipoxygenases, and Cytochrome P450 Pathways in the Tumorigenesis of Glioblastoma Multiforme, Including a Pan-Cancer Comparative Analysis.
Korbecki J; Rębacz-Maron E; Kupnicka P; Chlubek D; Baranowska-Bosiacka I
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765904
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.
Chacko AM; Li C; Pryma DA; Brem S; Coukos G; Muzykantov V
Expert Opin Drug Deliv; 2013 Jul; 10(7):907-26. PubMed ID: 23751126
[TBL] [Abstract][Full Text] [Related]
4. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME
Oncotarget; 2013 Apr; 4(4):502-30. PubMed ID: 23594434
[TBL] [Abstract][Full Text] [Related]
5. Strategies for enhanced drug delivery to the central nervous system.
Dwibhashyam VS; Nagappa AN
Indian J Pharm Sci; 2008; 70(2):145-53. PubMed ID: 20046703
[TBL] [Abstract][Full Text] [Related]
6. Pranlukast prevents cysteinyl leukotriene-induced emesis in the least shrew (Cryptotis parva).
Chebolu S; Wang Y; Ray AP; Darmani NA
Eur J Pharmacol; 2010 Feb; 628(1-3):195-201. PubMed ID: 19941848
[TBL] [Abstract][Full Text] [Related]
7. Intracarotid delivery of drugs: the potential and the pitfalls.
Joshi S; Meyers PM; Ornstein E
Anesthesiology; 2008 Sep; 109(3):543-64. PubMed ID: 18719453
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of infective from neoplastic brain lesions by dynamic contrast-enhanced MRI.
Haris M; Gupta RK; Singh A; Husain N; Husain M; Pandey CM; Srivastava C; Behari S; Rathore RK
Neuroradiology; 2008 Jun; 50(6):531-40. PubMed ID: 18379766
[TBL] [Abstract][Full Text] [Related]
9. Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.
Joshi S; Ornstein E; Bruce JN
Neurocrit Care; 2007; 6(3):200-12. PubMed ID: 17572864
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy in experimental brain tumor, part 2: pretreatment with leukotriene C4 prolongs survival.
Black P; Hand CM; Vender JR; Finkelstein SD
J Neurooncol; 1998 Jan; 36(1):7-19. PubMed ID: 9525821
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery to brain tumors.
Walker WL; Cook J
Bull Math Biol; 1996 Nov; 58(6):1047-74. PubMed ID: 8953256
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological blood-brain barrier modification for selective drug delivery.
Cloughesy TF; Black KL
J Neurooncol; 1995 Nov; 26(2):125-32. PubMed ID: 8787854
[TBL] [Abstract][Full Text] [Related]
13. Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats.
Chio CC; Lin SJ; Lin MT
J Neurooncol; 1995; 25(2):89-95. PubMed ID: 8543974
[TBL] [Abstract][Full Text] [Related]
14. Selective blood-tumor barrier disruption by leukotrienes.
Chio CC; Baba T; Black KL
J Neurosurg; 1992 Sep; 77(3):407-10. PubMed ID: 1506887
[TBL] [Abstract][Full Text] [Related]
15. Selective opening of the blood-tumor barrier by intracarotid infusion of leukotriene C4.
Black KL; King WA; Ikezaki K
J Neurosurg; 1990 Jun; 72(6):912-6. PubMed ID: 2338576
[TBL] [Abstract][Full Text] [Related]
16. Intracarotid infusion of leukotriene C4 selectively increases blood-brain barrier permeability after focal ischemia in rats.
Baba T; Black KL; Ikezaki K; Chen KN; Becker DP
J Cereb Blood Flow Metab; 1991 Jul; 11(4):638-43. PubMed ID: 1675639
[TBL] [Abstract][Full Text] [Related]
17. Selective opening of the blood-tumour barrier by intracarotid infusion of leukotriene C4.
Black KL; King WA; Ikezaki K
Acta Neurochir Suppl (Wien); 1990; 51():140-1. PubMed ID: 1982476
[TBL] [Abstract][Full Text] [Related]
18. Blood flow and blood-to-tissue transport in 9L gliosarcomas: the role of the brain tumor model in drug delivery research.
Fross RD; Warnke PC; Groothuis DR
J Neurooncol; 1991 Dec; 11(3):185-97. PubMed ID: 1823340
[TBL] [Abstract][Full Text] [Related]
19. Blood-brain barrier and new approaches to brain drug delivery.
Pardridge WM; Boado RJ; Black KL; Cancilla PA
West J Med; 1992 Mar; 156(3):281-6. PubMed ID: 1595245
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
